Skip to main content
Clinical Trials/NCT01930799
NCT01930799CompletedPhase 4

Bladder Management in Patients With Multiple Sclerosis: Optimizing Practice Patterns

Allergan1 site in 1 country120 target enrollmentStarted: August 1, 2013Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Phase 4
Status
Completed
Sponsor
Allergan
Enrollment
120
Locations
1
Primary Endpoint
Change From Baseline in the King's Health Questionnaire (KHQ) Domain Scores

Study Overview

Brief Summary

This study will assess the impact of a systematic bladder health screening and disease education regimen as well as the implementation of a referral process on the quality of life of multiple sclerosis patients with bladder dysfunction.

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Health Services Research
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Diagnosis of relapsing-remitting multiple sclerosis and currently being treated by study doctor

Exclusion Criteria

  • •Diagnosis of primary-progressive, secondary-progressive, or progressive-relapsing multiple sclerosis

Arms & Interventions

All Enrolled Patients

Other

Site will implement a systematic approach to screening bladder health dysfunction in multiple sclerosis patients, providing bladder health management education, and initiating appropriate urologist referrals.

Intervention: Systematic Screening and Education Regimen (Behavioral)

Outcomes

Primary Outcomes

Change From Baseline in the King's Health Questionnaire (KHQ) Domain Scores

Time Frame: Baseline, Month 6

The KHQ is a valid and reliable patient reported outcome measure for the assessment of quality of life in subjects with urinary incontinence that contains the following 8 domains: general health perception, incontinence impact, role limitations, physical limitations, social limitations, personal relations, emotions, sleep/energy, and severity measures. The KHQ domain scores are based on a scale of 0-100, with a lower score indicating less severity. Decreases in KHQ domain scores indicate an improvement in quality of life and increases in KHQ domain scores indicate a worsening in quality of life.

Secondary Outcomes

  • Percentage of Patients Who Agree/Completely Agree With Each Question on the Patient Post-Video Questionnaire(Baseline)

Investigators

Sponsor
Allergan
Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials